Table 1 Patient characteristics
Patient Group | |||
|---|---|---|---|
Characteristic | PPB (n = 291) | RRP (n = 873) | P Value |
Age, y | .11 | ||
Median range | 69 (41–80) | 68 (43–80) | |
Mean (SD) | 67.2 (6.7) | 66.6 (6.21) | |
Clinical stage | .47 | ||
T1 | 204 (70.1%) | 592 (67.8%) | |
T2 | 87 (29.9%) | 281 (32.2%) | |
Biopsy Gleason score | .73 | ||
6 | 235 (80.8%) | 722 (82.7%) | |
7 | 36 (12.4%) | 104 (11.9%) | |
≥8 | 20 (6.8%) | 47 (5.4%) | |
Pretherapy PSA value, ng/mL | .95 | ||
Median (IQR) | 5.7 (4.1-7.7) | 5.8 (4.1-7.6) | |
Range | 0.6-17.5 | 0.6-23.1 | |
Time from therapy to death or last follow-up, y | .008 | ||
Median | 3.1 | 3.6 | |
Maximum | 6.9 | 7.5 | |
Systemic progression | 4 (1.4%) | 4 (0.5%) | .10 |
Biopsy-proven local recurrence | 1 (0.3%) | 5 (0.6%) | .63 |